Change of lot or extension of reference standard shelf-life is considered low risk and should be downgraded from prior-approval to being managed in the Pharmaceutical Quality System (PQS) only based on a science and risk-based approach.
Julie Barthuet
Advertisement
Julie Barthuet is head Regulatory CMC&D Vaccines at Sanofi Vaccines.
Articles by Julie Barthuet
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
2
Establishing Risk Assessments for AI in Bio-Manufacturing
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
5
